Ying-Ming Tsai
Overview
Explore the profile of Ying-Ming Tsai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
868
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsai Y, Lee Y, Chang C, Tsai H, Wu Y, Lee H, et al.
Life Sci
. 2025 Jan;
363:123408.
PMID: 39832739
Pulmonary disorders are exacerbated by high blood sugar, leading to a disordered immune defense and increased susceptibility to infection. Type 2 diabetes mellitus (T2D) is characterized by insulin resistance and...
2.
Kan J, Lee H, Hou M, Tsai H, Jian S, Chang C, et al.
Cell Death Dis
. 2024 Dec;
15(12):899.
PMID: 39695088
The Triple-Negative Breast Cancer (TNBC) subtype constitutes 15-20% of breast cancer cases and is associated with the poorest clinical outcomes. Distant metastasis, particularly to the lungs, is a major contributor...
3.
Chiang H, Wu K, Tsai H, Ong C, Chang C, Wu Y, et al.
Am J Cancer Res
. 2024 Nov;
14(10):4817-4829.
PMID: 39553230
Lung adenocarcinoma (LUAD) carries a poor prognosis at advanced stages underscoring the need to elucidate the underlying molecular mechanisms driving its pathogenesis. This study aimed to investigate the roles of...
4.
Dai C, Tsai Y, Chang C, Tsai H, Wu K, Wu Y, et al.
Int J Biol Sci
. 2024 Nov;
20(14):5531-5547.
PMID: 39494341
The global prevalence of type 2 diabetes mellitus (T2DM) continues to rise. Therefore, it has become a major concern health issue worldwide. T2DM leads to various complications, including metabolic-associated fatty...
5.
Wu K, Chang C, Tsai Y, Lai J, Hung J, Lin Y, et al.
Am J Cancer Res
. 2024 May;
14(4):1561-1576.
PMID: 38726259
Lung squamous cell carcinoma (LUSC) remains a difficult-to-treat disease with a poor prognosis. While prominin-1 () is largely investigated in a variety of malignancies, the role of prominin-2 (), the...
6.
Chiang H, Ong C, Chang C, Wu K, Wu Y, Lai J, et al.
Am J Cancer Res
. 2024 Mar;
14(2):854-868.
PMID: 38455397
The poor outcome of patients with lung adenocarcinoma (LUAD) highlights the importance to identify novel effective prognostic markers and therapeutic targets. Long noncoding RNAs (lncRNAs) have generally been considered to...
7.
Tsai Y, Wu K, Huang Y, Wu Y, Chang C, Chang Y, et al.
Mol Med Rep
. 2023 Nov;
29(1).
PMID: 37997813
Lung adenocarcinoma (LUAD) is one of the deadliest cancers regarding both mortality rate and number of deaths and warrants greater effort in the development of potential therapeutic targets. The enhancer...
8.
Hsu C, Tsai Y, Yang S, Hsu J
Kaohsiung J Med Sci
. 2023 Sep;
39(11):1155-1156.
PMID: 37698283
No abstract available.
9.
Wu Y, Hsu Y, Huang Y, Su Y, Wu K, Chang C, et al.
Theranostics
. 2023 Aug;
13(13):4412-4429.
PMID: 37649596
Lung cancer is associated with a high mortality rate and often complicated with malignant pleural effusion (MPE), which has a very poor clinical outcome with a short life expectancy. However,...
10.
Chang C, Huang Y, Chiang H, Wu Y, Wu K, Chang Y, et al.
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36613882
Lung cancer is one of the deadliest cancers worldwide, including in Taiwan. The poor prognosis of the advanced lung cancer lies in delayed diagnosis and non-druggable targets. It is worth...